Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib Combinations in Bim-Deleted/Low-Abundance EGFR-Mutant NSCLC
NCT03267654Phase 2Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2017
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Qilu Pharmaceutical. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03267654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03267654.